Document is current
Any future updates will be listed below
-
Authors
Escribá, Pablo V.
Gil-Agudo, Ángel M. https://orcid.org/0000-0001-5082-4225
Vidal Samsó, Joan
Sánchez-Raya, Judith
Salvador-de la Barrera, Sebastián https://orcid.org/0000-0002-9810-7548
Soto-León, Vanesa
León-Álvarez, Natacha
Méndez Ferrer, Bosco
Membrilla-Mesa, Miguel David
Redondo Galán, Carolina
Benito-Penalva, Jesús
Montoto-Marqués, Antonio https://orcid.org/0000-0003-1773-365X
Medel Rebollo, Javier
Palazón García, Ramiro
Gutiérrez Henares, Francisco
Miralles, Marc
Torres, Manuel https://orcid.org/0000-0002-5076-8486
Nieto-Librero, Ana B. https://orcid.org/0000-0001-6643-247X
García Marco, David
Gómez, Carmela https://orcid.org/0000-0002-9041-886X
Jimeno, David
Oliviero, Antonio https://orcid.org/0000-0001-7723-0478
- License Information
-
More Information
Article History
Received: 22 September 2023
Revised: 31 May 2024
Accepted: 5 June 2024
First Online: 19 June 2024
Competing interests
: CG and DJ are employees of Neurofix Pharma S.A. PVE is a cofounder and shareholder of the company Neurofixpharma SA AO, AMGA, JVS, JSR, SSB, NLA, BMF, MDMM, CRG, JBP, AMM, JMR, RPG, DGM, and FGH were paid for activities associated with the clinical trial by Neurofix Pharma S.A.
: This study was approved by the Institutional Review Board (Regional Committee of Ethics for Research with Medicines, CEIm, of the Community of Madrid) and by the Spanish Agency of Medicines and Health Products (AEMPS), and participants provided written informed consent before participating in the study. This work was carried out in compliance with applicable regulations and guidelines, following the principles of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines.
